Tango Therapeutics stock rockets 53% on pancreatic cancer data

Tango Therapeutics (NASDAQ:TNGX) shares climbed to a record high after the company unveiled initial clinical data showing that its experimental oncology asset, vopimetostat, shrunk tumors in nearly all evaluated pancreatic cancer patients when combined with Revolution Medicines' daraxonrasib.

The stock surged 53 percent to close at $30.93 in New York trading, extending Tango's year-to-date gain to 254 percent.

The market rally highlights expanding investor confidence in therapeutic combinations engineered to target high-refractory solid tumors, particularly within pancreatic ductal adenocarcinoma, an aggressive malignancy historically linked to low survival rates.

Data from the ongoing Phase 1/2 clinical study showed a 92 percent objective response rate among 12 evaluable pancreatic cancer patients who received the combination regimen.

Out of the 12 participants tracked in this arm, 11 experienced visible tumor shrinkage.

Durability metrics from the six-month follow-up window revealed that 90 percent of patients remained entirely progression-free, with the dual therapy achieving a 100 percent overall disease control rate.

Formal confirmation scans are currently pending for two of the responding patients.

The study also yielded positive signals across alternative treatment tracks and adjacent indications.

A small cohort of non-small cell lung cancer patients treated with the vopimetostat-daraxonrasib regimen recorded a 100 percent objective response rate.

Meanwhile, a separate arm of the trial evaluating vopimetostat alongside a different Revolution Medicines compound, zoldonrasib, demonstrated a 52 percent response rate and a 74 percent six-month progression-free survival rate among its pancreatic cancer participants.

Patient safety profiles remained manageable throughout the multi-center trial.

Participants experienced relatively few severe or serious adverse effects from either combination regimen, reinforcing the potential safety viability of the dual-action architecture.

The underlying science depends on a synthetic lethality approach, where vopimetostat specifically targets the MTAP gene, an enzyme deletion frequently found in pancreatic tumors. Daraxonrasib blocks mutated RAS proteins.

Because malignant cells regularly develop resistance to direct RAS inhibitors over prolonged treatment cycles, the industry has engaged in a development race to identify partner compounds capable of disrupting alternative tumor escape pathways to prolong survival metrics.

Backed by the strength of the early-stage clinical signal, Tango plans to rapidly advance the vopimetostat and daraxonrasib combination into a large-scale Phase 3 clinical trial.

The upcoming registration-enabling study will analyze the dual regimen as an initial, first-line therapy option for individuals newly presenting with advanced pancreatic cancer, with patient enrollment scheduled to commence before the end of the year.